xenon has been researched along with Cerebral Infarction, Middle Cerebral Artery in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dandekar, MP; Devaraj, S; Huang, SL; McPherson, DD; Morales, R; Peng, T; Yin, X | 1 |
| Guo, ZN; Wang, J; Wu, J; Yang, G; Yang, Y; Zhou, HW | 1 |
| Abraini, JH; Haelewyn, B; Risso, JJ; Rouillon, C | 1 |
| Cattano, D; Giunta, F; Gu, J; Limatola, V; Ma, D; Maze, M; Ward, P | 1 |
| Abraini, JH; Colloc'h, N; David, HN; Haelewyn, B; Risso, JJ | 1 |
| Aronowski, J; Britton, GL; Holland, CK; Huang, SL; Kee, PH; Kim, H; McPherson, DD | 1 |
| Ezzeddine, MA | 1 |
| Chang, YF; Gebel, JM; Goldstein, S; Grahovac, SZ; Jovin, TG; Kanal, E; Wechsler, LR; Yonas, H | 1 |
| Franks, NP; Grocott, HP; Homi, HM; Ma, D; Maze, M; Warner, DS; Yokoo, N | 1 |
| Abraini, JH; Buisson, A; David, HN; Lemaire, M; MacKenzie, ET; Nicole, O | 1 |
| Chang, Y; Johnson, DW; Kuwabara, H; Meltzer, CC; Nemoto, EM; Pindzola, RR; Price, JC; Sashin, D; Yonas, H | 1 |
| Abraini, JH; David, HN; Lemaire, M | 1 |
1 review(s) available for xenon and Cerebral Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon.
Topics: Anesthetics, Inhalation; Animals; Brain Ischemia; Cardiopulmonary Bypass; Cell Death; Central Nervous System Stimulants; Humans; Infarction, Middle Cerebral Artery; Methamphetamine; Neuroprotective Agents; Neurotoxins; Nitrous Oxide; Postoperative Complications; Rats; Xenon | 2005 |
11 other study(ies) available for xenon and Cerebral Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Repetitive xenon treatment improves post-stroke sensorimotor and neuropsychiatric dysfunction.
Topics: Animals; Anxiety; Brain Injuries; Cytokines; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Rats; Xenon | 2022 |
Xenon-enhanced CT assessment of cerebral blood flow in stroke-in-progress patients with unilateral internal carotid artery or middle cerebral artery stenosis.
Topics: Adult; Aged; Carotid Stenosis; Cerebral Cortex; Female; Humans; Infarction, Middle Cerebral Artery; Male; Middle Aged; Regional Blood Flow; Stroke; Tomography, X-Ray Computed; Xenon | 2013 |
Functional (neurologic) recovery following transient focal cerebral ischemia in the rat requires at least 80% of ipsilateral cortical and subcortical integrity.
Topics: Animals; Brain; Cerebral Cortex; Cerebral Infarction; Cytoprotection; Disability Evaluation; Disease Progression; Functional Laterality; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Neuroprotective Agents; Nitrous Oxide; Rats; Rats, Sprague-Dawley; Recovery of Function; Reperfusion Injury; Severity of Illness Index; Xenon | 2008 |
Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion.
Topics: Animals; Brain; Cohort Studies; Disability Evaluation; Disease Models, Animal; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Infarction, Middle Cerebral Artery; Ischemic Preconditioning; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nitrogen; Oxygen; Proto-Oncogene Proteins c-akt; Random Allocation; Sex Characteristics; Stroke; Treatment Outcome; Xenon | 2010 |
Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.
Topics: Animals; Brain Ischemia; Catalytic Domain; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Fibrinolysin; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Male; Models, Molecular; Neuroprotective Agents; Protein Conformation; Rats; Rats, Sprague-Dawley; Serine Proteases; Stroke; Tissue Plasminogen Activator; Xenon | 2010 |
In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes.
Topics: Animals; Brain Ischemia; Cell Survival; Drug Delivery Systems; Infarction, Middle Cerebral Artery; Injections, Intravenous; Liposomes; Male; Models, Animal; Neurons; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Ultrasonography; Xenon | 2010 |
From xenon to argon: a more clinically accessible neuroprotectant?
Topics: Animals; Argon; Humans; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Xenon | 2011 |
The cortical ischemic core and not the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion.
Topics: Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Disease Progression; Female; Humans; Infarction, Middle Cerebral Artery; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Severity of Illness Index; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome; Xenon | 2003 |
The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice.
Topics: Administration, Inhalation; Animals; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Xenon | 2003 |
Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration.
Topics: Anesthetics, Inhalation; Animals; Infarction, Middle Cerebral Artery; Mice; Neuroprotective Agents; Nitrous Oxide; Pulmonary Alveoli; Receptors, N-Methyl-D-Aspartate; Stroke; Xenon | 2004 |
Identification of hemodynamic compromise by cerebrovascular reserve and oxygen extraction fraction in occlusive vascular disease.
Topics: Aged; Cerebral Infarction; Cerebrovascular Circulation; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Middle Aged; Oxygen; Positron-Emission Tomography; Xenon | 2004 |